Respiratory medicine
-
Respiratory medicine · Jul 2011
Randomized Controlled Trial Multicenter StudyEffect of indacaterol on exercise endurance and lung hyperinflation in COPD.
Indacaterol is a novel, inhaled, once-daily ultra long-acting β(2)-agonist (ultra-LABA) for the treatment of COPD. This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD. ⋯ In conclusion, indacaterol treatment improved the ability of patients with COPD to exercise. In addition, the improvements observed in resting and end-exercise IC indicate reductions in lung hyperinflation after 3 weeks treatment (ClinicalTrials.gov registration number: NCT00620022).
-
Respiratory medicine · Jul 2011
The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia.
To determine the impact of COPD on intensive care unit (ICU) mortality in patients with VAP. ⋯ COPD, SAPS II, and shock at VAP diagnosis are independently associated with ICU mortality in patients who present VAP.
-
Respiratory medicine · Jul 2011
Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin.
COPD is characterized by a multi-component character involving a state of low-grade systemic inflammation and an increased prevalence of cardiovascular co-morbidity. The role of circulating leptin and other adipokines in the involvement of the systemic inflammation in COPD is only studied scarcely. ⋯ In men with clinically stable COPD, leptin, adiponectin and resistin appear to be physiologically regulated, while in women, leptin metabolism is altered. Leptin secretion is increased in COPD women when compared to healthy women and compared to COPD men, and to a greater extent in overweight women with COPD.
-
Respiratory medicine · Jul 2011
Retail sales of inhalation devices in European countries: so much for a global policy.
To evaluate the retail sales of pressurised metered-dose inhalers (pMDIs), dry-powder inhalers (DPIs) and liquids for nebulisation in 16 European countries. ⋯ We found a high degree of variability in inhaler prescription between European countries. Differing health policies, costs, health insurance issues, pharmaceutical/commercial aspects and prescribers' and patients' preferences may explain this variation. We suggest a need for more uniform, outcome-led inhaler prescribing practice across Europe to improve the efficacy and cost effectiveness of the treatment of obstructive airways diseases.
-
Respiratory medicine · Jul 2011
Type II diabetes mellitus is associated with decreased measures of lung function in a clinical setting.
Type II diabetes mellitus has been associated with reduced forced expiratory volume in first second (FEV(1)) and forced vital capacity (FVC). We investigated if this relationship is maintained in a clinical setting, independent of respiratory infections and heart failure. ⋯ In a clinical setting, patients with diabetes have decreased lung function compared to their non-diabetic counterparts, independent of respiratory infections and heart failure.